Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 521-527

  Thomas, Jennifer K ^a,c   Forrest, Alan ^a   Bhavnani, Sujata M ^a   Hyatt, Judith M ^a   Cheng, Angela ^b   Ballow, Charles H ^a   Schentag, Jerome J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFMENOXIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTION; PRIORITY JOURNAL;

EID: 0031940776     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.521     Document Type: Article

References (27)

1. Akaike, H. 1979. A bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
2. ASM Task Force on Antibiotic Resistance. 1995. Report of the ASM Task Force on Antibiotic Resistance. American Society for Microbiology, Washington, D.C.
3. Ballow, C. H., and J. J. Schentag. 1992. Trends in antibiotic utilization and bacterial resistance. Report of the national nosocomial resistance surveillance group. Diagn. Microbiol. Infect. Dis. 15:37S-42S.
4. Bax, R. P. 1997. Antibiotic resistance: a view from the pharmaceutical industry. Clin. Infect. Dis. 24(Suppl. 1):S151-S153.
5. Bhavnani, S. M., A. Cheng, C. H. Ballow, and A. Forrest. 1996. Modelling the PDs of SITs for ceftazidime (Ctz). Ctz/tobramycin (C+T), ciprofloxacin (Cip), and Cip/piperacillin (C+P), in acutely ill patients, abstr. A99, p. 20. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
7. Cheng, A., A. Forrest, C. H. Ballow, and J. J. Schentag. Pharmacodynamics of intravenous ciprofloxacin with and without piperacillin in seriously ill patients. Submitted for publication.
8. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
9. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
10. D'Argenio, D. Z., and A. Schumitzky. 1992. ADAPT II users manual. Biomedical simulations resource. University of Southern California, Los Angeles, Calif.
11. Drusano, G. L., D. E. Johnson, M. Rone, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37: 483-490.
12. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, R. H. Johnson, S. O. Heard, G. Wunderink, J. W. Caldwell, J. J. Schentag, G. A. Siami, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, and R. M. Echols. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
13. Fish, D. N., S. C. Piscitelli, and L. H. Danziger. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic class and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
14. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
15. Gold, H. S., and R. C. Moellering. 1996. Antimicrobial-drug resistance. N. Engl. J. Med. 335:1445-1453.
16. Goss, T. F., A. Forrest, D. E. Nix, C. H. Ballow, M. C. Birmingham, T. J. Cumbo, and J. J. Schentag. 1994. Mathematical examination of dual individual principles. II. The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann. Pharmacother. 28:863-868.
17. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. 28:143-160.
18. Madaras-Kelly, K. J., B. E. Ostergaard, L. B. Hovde, and J. C. Rotschafer. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632.
19. Marchbanks, C. R., J. R. McKiel, D. H. Gilbert, N. J. Robillard, B. Painter, S. H. Zinner, and M. N. Dudley. 1993. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruiginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob. Agents Chemother. 37:1756-1763.
20. Medeiros, A. A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24:(Suppl.): S19-S45.
21. National Committee for Clinical Laboratory Standards. 1995. Minimum inhibitory concentration interpretive standards for organisms other than Haemophilus spp., Neisseria gonorrheas, and Streptococcus, table 2. M7-A3 (M100-S6). National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch. Intern. Med. 149:2269-2273.
23. Schentag, J. J., D. P. Reitberg, and T. J. Cumbo. 1984. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Am. J. Med. 77:(Suppl.6A):34-42.
24. Schentag, J. J., I. L. Smith, D. J. Swanson, C. DeAngelis, J. E. Fracasso, A. Vari, and J. W. Vance. 1984. Role for dual individualization with cefmenoxime. Am. J. Med. 77:(Suppl.):43-50.
25. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. I. Relationships between AUC and MIC and the area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Drug Intell. Clin. Pharm. 25:1050-1057.
26. Schentag, J. J., D. E. Nix, A. Forrest, and M. H. Adelman. 1996. AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann. Pharmacother. 30:1029-1031.
27. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.